David Young - Oct 1, 2025 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role
Pres. Research & Development, Director
Signature
/s/ David Young by John J. Wolfel, as Attorney-in-Fact
Stock symbol
PCSA
Transactions as of
Oct 1, 2025
Transactions value $
$0
Form type
4
Date filed
10/3/2025, 04:25 PM
Previous filing
Sep 18, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Young David Pres. Research & Development, Director C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH /s/ David Young by John J. Wolfel, as Attorney-in-Fact 2025-10-03 0001378166

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCSA Restricted Stock Units Award $0 +111K $0.00 111K Oct 1, 2025 Common Stock 111K $0.00 Direct F1
transaction PCSA Stock Options (Right to Buy) Award $0 +333K $0.00 333K Oct 1, 2025 Common Stock 333K $0.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on October 1, 2026, and one-thirty-sixth each month thereafter until fully vested on October 1, 2028.
F2 Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.